According to Atlas, the £16.9m investment, which will be drawn down over three years, will be used to accelerate the global launch of the Velox point-of-care products for Chlamydia and gonorrhoea. It will also be used for the development of other infectious-disease tests and expand the immunoassay capability of the Velox system.
Velox is said to be a highly novel molecular diagnostic system for the ultra-rapid diagnosis of a range of infectious diseases using either nucleic acid or immuno assays and is based on a patent-protected electrochemical sensor.
It is claimed that the Velox system will make it possible, for the first time, to carry out infectious-disease tests in primary-care clinics and GP surgeries that are as accurate as those carried out in hospital laboratories.
The new investors in this series-B financing are Novartis Venture Funds, LSP (Life Sciences Partners), BB Biotech Ventures and Johnson and Johnson Development.
Florent Gros, managing director, Novartis Venture Funds, said: ‘We have searched long and hard for novel molecular diagnostic technologies and the Velox platform is a very ingenious solution to the key issues that have hindered the development of ultra-rapid and highly sensitive point-of-care molecular diagnostic instrumentation.
‘Combined with the ability to make immunoassay tests, this makes for a diversified all-in-one diagnostic platform that will be commercialised around the end of 2012.’
The newly announced financing follows a £1.5m round in February 2011 supported by Consort Medical and other investors.
Experts speculate over cause of Iberian power outages
The EU and UK will be moving towards using Grid Forming inverters with Energy Storage that has an inherent ability to act as a source of Infinite...